Microba Life Sciences Limited
Microba Life Sciences Limited MAP.AX Peers
See (MAP.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MAP.AX | A$0.09 | +0.00% | 38.1M | -2.83 | -A$0.03 | N/A |
| SHL.AX | A$26.79 | +0.00% | 12.8B | 23.44 | A$1.14 | +4.00% |
| IDX.AX | A$2.54 | +0.00% | 941.7M | 126.50 | A$0.02 | +2.29% |
| ACL.AX | A$2.78 | +0.00% | 547.8M | 18.73 | A$0.15 | +4.45% |
| HLS.AX | A$0.79 | +0.00% | 544.6M | -0.77 | -A$0.98 | +84.63% |
| MVF.AX | A$0.71 | +0.00% | 280.5M | -72.00 | -A$0.01 | +7.08% |
| GSS.AX | A$0.37 | +0.00% | 86.3M | -3.80 | -A$0.10 | N/A |
| PEB.AX | A$0.10 | +0.00% | 81.2M | -3.33 | -A$0.03 | N/A |
| IIQ.AX | A$0.37 | +0.00% | 41.3M | -5.29 | -A$0.07 | N/A |
| CTE.AX | A$0.75 | +0.00% | 36.4M | 18.63 | A$0.04 | +9.40% |
Stock Comparison
MAP.AX vs SHL.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, SHL.AX has a market cap of 12.8B. Regarding current trading prices, MAP.AX is priced at A$0.09, while SHL.AX trades at A$26.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas SHL.AX's P/E ratio is 23.44. In terms of profitability, MAP.AX's ROE is -0.48%, compared to SHL.AX's ROE of +0.07%. Regarding short-term risk, MAP.AX is more volatile compared to SHL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs IDX.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, IDX.AX has a market cap of 941.7M. Regarding current trading prices, MAP.AX is priced at A$0.09, while IDX.AX trades at A$2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas IDX.AX's P/E ratio is 126.50. In terms of profitability, MAP.AX's ROE is -0.48%, compared to IDX.AX's ROE of +0.01%. Regarding short-term risk, MAP.AX is less volatile compared to IDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs ACL.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, ACL.AX has a market cap of 547.8M. Regarding current trading prices, MAP.AX is priced at A$0.09, while ACL.AX trades at A$2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas ACL.AX's P/E ratio is 18.73. In terms of profitability, MAP.AX's ROE is -0.48%, compared to ACL.AX's ROE of +0.18%. Regarding short-term risk, MAP.AX is less volatile compared to ACL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs HLS.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, HLS.AX has a market cap of 544.6M. Regarding current trading prices, MAP.AX is priced at A$0.09, while HLS.AX trades at A$0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas HLS.AX's P/E ratio is -0.77. In terms of profitability, MAP.AX's ROE is -0.48%, compared to HLS.AX's ROE of -0.02%. Regarding short-term risk, MAP.AX is less volatile compared to HLS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs MVF.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, MVF.AX has a market cap of 280.5M. Regarding current trading prices, MAP.AX is priced at A$0.09, while MVF.AX trades at A$0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas MVF.AX's P/E ratio is -72.00. In terms of profitability, MAP.AX's ROE is -0.48%, compared to MVF.AX's ROE of -0.01%. Regarding short-term risk, MAP.AX is less volatile compared to MVF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs GSS.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, GSS.AX has a market cap of 86.3M. Regarding current trading prices, MAP.AX is priced at A$0.09, while GSS.AX trades at A$0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas GSS.AX's P/E ratio is -3.80. In terms of profitability, MAP.AX's ROE is -0.48%, compared to GSS.AX's ROE of -0.39%. Regarding short-term risk, MAP.AX is less volatile compared to GSS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs PEB.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, PEB.AX has a market cap of 81.2M. Regarding current trading prices, MAP.AX is priced at A$0.09, while PEB.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas PEB.AX's P/E ratio is -3.33. In terms of profitability, MAP.AX's ROE is -0.48%, compared to PEB.AX's ROE of -0.57%. Regarding short-term risk, MAP.AX is less volatile compared to PEB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs IIQ.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, IIQ.AX has a market cap of 41.3M. Regarding current trading prices, MAP.AX is priced at A$0.09, while IIQ.AX trades at A$0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas IIQ.AX's P/E ratio is -5.29. In terms of profitability, MAP.AX's ROE is -0.48%, compared to IIQ.AX's ROE of -0.36%. Regarding short-term risk, MAP.AX is less volatile compared to IIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs CTE.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, CTE.AX has a market cap of 36.4M. Regarding current trading prices, MAP.AX is priced at A$0.09, while CTE.AX trades at A$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas CTE.AX's P/E ratio is 18.63. In terms of profitability, MAP.AX's ROE is -0.48%, compared to CTE.AX's ROE of +1.33%. Regarding short-term risk, MAP.AX is more volatile compared to CTE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs BDX.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, BDX.AX has a market cap of 24.5M. Regarding current trading prices, MAP.AX is priced at A$0.09, while BDX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas BDX.AX's P/E ratio is -2.23. In terms of profitability, MAP.AX's ROE is -0.48%, compared to BDX.AX's ROE of -0.90%. Regarding short-term risk, MAP.AX is less volatile compared to BDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs LDX.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, LDX.AX has a market cap of 19.5M. Regarding current trading prices, MAP.AX is priced at A$0.09, while LDX.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas LDX.AX's P/E ratio is -2.60. In terms of profitability, MAP.AX's ROE is -0.48%, compared to LDX.AX's ROE of -0.59%. Regarding short-term risk, MAP.AX is less volatile compared to LDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs RHY.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, RHY.AX has a market cap of 15.7M. Regarding current trading prices, MAP.AX is priced at A$0.09, while RHY.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas RHY.AX's P/E ratio is -5.40. In terms of profitability, MAP.AX's ROE is -0.48%, compared to RHY.AX's ROE of -0.76%. Regarding short-term risk, MAP.AX is less volatile compared to RHY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs GTG.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, GTG.AX has a market cap of 5.7M. Regarding current trading prices, MAP.AX is priced at A$0.09, while GTG.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas GTG.AX's P/E ratio is -3.90. In terms of profitability, MAP.AX's ROE is -0.48%, compared to GTG.AX's ROE of -3.62%. Regarding short-term risk, MAP.AX is more volatile compared to GTG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs IBX.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, IBX.AX has a market cap of 2.4M. Regarding current trading prices, MAP.AX is priced at A$0.09, while IBX.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas IBX.AX's P/E ratio is -0.24. In terms of profitability, MAP.AX's ROE is -0.48%, compared to IBX.AX's ROE of +0.55%. Regarding short-term risk, MAP.AX is less volatile compared to IBX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs WFL.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 38.1M. In comparison, WFL.AX has a market cap of 1.5M. Regarding current trading prices, MAP.AX is priced at A$0.09, while WFL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -2.83, whereas WFL.AX's P/E ratio is -0.10. In terms of profitability, MAP.AX's ROE is -0.48%, compared to WFL.AX's ROE of +11.65%. Regarding short-term risk, MAP.AX is more volatile compared to WFL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.